Sermorelin

Sermorelin is understood to bind the growth-hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor expressed on anterior pituitary somatotrophs. Because it reproduces the active fragment of endogenous GHRH, it engages the same recognition site rather than acting on the somatostatin or ghrelin/GHS receptor systems. This receptor selectivity is thought to underlie its endogenous, secretagogue-style profile.

Upon GHRHR engagement, the receptor is understood to couple to Gs proteins that activate adenylate cyclase, raising intracellular cyclic AMP and downstream protein kinase A activity. This signaling cascade is understood to increase transcription and pulsatile secretion of stored growth hormone from somatotroph cells. Elevated PKA tone is also linked to calcium influx that supports the exocytotic release step.

GHRH-family peptides are understood as components of the hypothalamic-pituitary neuroendocrine axis, where the native ligand originates from arcuate nucleus neurons. Sermorelin itself acts primarily at the peripheral pituitary, and limited direct neural activity beyond this neuroendocrine signaling is described. GH/IGF-1 axis tone is also associated with sleep-architecture and slow-wave sleep parameters.

By promoting pituitary-driven GH pulses, Sermorelin is associated with downstream hepatic IGF-1 generation and the broader somatotropic regulatory axis governing protein, lipid, and glucose metabolism. Because the response remains under hypothalamic somatostatin feedback, it is understood to preserve physiologic pulsatility rather than overriding the loop. It is also understood to relate to body-composition, recovery, and metabolic regulatory pathways.